0
Business
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
April 12, 2026
Quartz
Scroll
SLNO shares surge as Neurocrine inks 2.9B cash deal to acquire it at 53 a share, adding Vykat XR and expanding its rare disease and endocrinology portfolio.
Quartz
Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.
United States of America
Bias: lean left